# Silver nitrate: a novel therapeutic approach for refractory Seroma following body malodor surgery

**Authors:** Wen-Tsao Ho

PMC · DOI: 10.1093/jscr/rjae067 · 2024-02-13

## TL;DR

Silver nitrate successfully treated persistent fluid collections after body odor surgery, offering a new option when traditional methods fail.

## Contribution

Demonstrates silver nitrate as a novel and effective treatment for refractory seroma after axillary osmidrosis surgery.

## Key findings

- Silver nitrate resolved refractory seromas within 7 and 14 days in two cases.
- Silver nitrate has antiseptic, anti-inflammatory, and wound-healing properties beneficial for seroma treatment.

## Abstract

Seroma, a fluid collection that can develop after surgery, can be a challenging complication to manage. Conventional treatment options, such as quilting suture and drainage tubes, may not be effective in resolving refractory seromas. This article presents two cases of refractory seroma after axillary osmidrosis surgery that were successfully treated with silver nitrate. Silver nitrate, a topical agent with antiseptic, anti-inflammatory, and wound-healing properties, has been shown to be effective in treating perianal fistulas and persistent tracheocutaneous fistulas. In both cases presented here, silver nitrate resulted in complete seroma resolution within 7 and 14 days, respectively. This study suggests that silver nitrate may be a promising treatment option for refractory seroma after axillary osmidrosis surgery. Further research is warranted to validate these findings and establish optimal dosage and treatment protocols.

## Linked entities

- **Chemicals:** silver nitrate (PubChem CID 24470)

## Full-text entities

- **Diseases:** inflammatory (MESH:D007249), tracheocutaneous fistulas (MESH:D005402), perianal fistulas (MESH:D000694), Seroma (MESH:D049291)
- **Chemicals:** Silver nitrate (MESH:D012835)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10871765/full.md

---
Source: https://tomesphere.com/paper/PMC10871765